NASDAQ: PMCB - PharmaCyte Biotech, Inc.

Altı ay boyunca karlılık: -23.79%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı PharmaCyte Biotech, Inc.

Gelişmiş program Basit grafik
Financial Markets by TradingView

Şirket hakkında

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes.

daha fazla ayrıntı
The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Karşılaştırma listesine ekle
İzleme listesine ekle
Portföye ekle
Fiyat bildirimi ekle

IPO date 2010-09-17
ISIN US71715X2036
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://pharmacyte.com
Цена ао 2.44
Günlük fiyat değişimi: +0.641% (1.56)
Haftalık fiyat değişimi: -4.27% (1.64)
Aylık fiyat değişimi: -8.19% (1.71)
3 ayda fiyat değişimi: -14.67% (1.84)
Altı ayda fiyat değişimi: -23.79% (2.06)
Yıllık fiyat değişimi: -27.31% (2.16)
3 yılda fiyat değişimi: -38.67% (2.56)
5 yılda fiyat değişimi: +4 398.57% (0.0349)
10 yılda fiyat değişimi: 0% (1.57)
Yılbaşından bu yana fiyat değişimi: -8.19% (1.71)
Tüm parametreler

Hafife alma

İsim Anlam Seviye
P/S 0 0
P/BV 0.514 10
P/E 60.86 1
EV/EBITDA -89.49 0
Toplam: 3.63

Yeterlik

İsim Anlam Seviye
ROA, % 0.5012 1
ROE, % 0.5949 1
Toplam: 0.3333

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0.0212

Görev

İsim Anlam Seviye
Debt/EBITDA 0 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -98.14 0
karlılık Ebitda, % -108.78 0
karlılık EPS, % -1344.13 0
Toplam: 0
Daha fazla ayrıntı

Kurumlar Hacim Paylaşmak, %
K2 Principal Fund, L.P. 304613 0.01
Geode Capital Management, LLC 215637 0.01
Vanguard Group Inc 171335 0.01
Equitec Proprietary Markets LLC 82727 0
Sabby Management, LLC 82373 0
Renaissance Technologies, LLC 38100 0
Dimensional Fund Advisors LP 29307 0
Blackrock Inc. 28769 0
Citadel Advisors Llc 28618 0
Schonfeld Strategic Advisors LLC 23200 0

ETF Paylaşmak, % Yıllık karlılık, % Temettüler, %
Dimensional U.S. Targeted Value ETF 0.00013 26.01 1.93487
Dimensional U.S. Core Equity 2 ETF 0.00006 30.76 1.47098



Süpervizör İş unvanı Ödeme Doğum yılı
Mr. Joshua N. Silverman Interim CEO, Interim President & Interim Chairman 197.92k 1970 (55 yıllar)
Mr. Carlos A. Trujillo CPA, CPA Chief Financial Officer 380k 1958 (67 yıllar)
Dr. Jose L. Iglesias M.D. Consulting Chief Medical Officer N/A 1957 (68 yıllar)
Dr. Hans-Peter Hammes Member of Medical & Scientific Advisory Board and Consultant N/A

Adres: United States, Las Vegas. NV, 3960 Howard Hughes Parkway - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://pharmacyte.com